Company Description
IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell product candidates for the treatment of cancer and autoimmune diseases.
Its products include INB-400, which is in Phase 2 clinical trial to treat newly diagnosed glioblastoma (GBM); INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of GBM; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with hematologic malignancies undergoing hematopoietic stem cell transplantation.
The company also develops INB-619, a gamma-delta TCE targeting CD19 for both oncology and autoimmune diseases; INB-300, a nsCAR-enabled DeltEx product candidates targeting difficult liquid tumors and extracranial solid tumors; and INB-500, an induced pluripotent stem cell derived gamma-delta T cells that are in preclinical phase for treatment of cancer.
The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020.
IN8bio, Inc. was incorporated in 2016 and is based in New York, New York.
| Country | United States |
| Founded | 2016 |
| IPO Date | Jul 30, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 18 |
| CEO | Tai-Wei Ho |
Contact Details
Address: 350 5th Avenue, Suite 5330 New York, New York 10118 United States | |
| Phone | 646 600 6438 |
| Website | in8bio.com |
Stock Details
| Ticker Symbol | INAB |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $10.00 |
| CIK Code | 0001740279 |
| CUSIP Number | 45674E109 |
| ISIN Number | US45674E1091 |
| Employer ID | 82-5462585 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Tai-Wei Ho | Co-Founder, President, Chief Executive Officer and Director |
| Patrick McCall CPA | Chief Financial Officer and Secretary |
| Dr. Kate Rochlin Ph.D. | Chief Operating Officer |
| Dr. Lawrence S. Lamb Ph.D. | Executive Vice President, Co-Founder and Chief Scientific Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 28, 2025 | 8-K | Current Report |
| Apr 28, 2025 | 8-K | Current Report |
| Mar 17, 2025 | ARS | Filing |
| Mar 17, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Mar 17, 2025 | DEF 14A | Other definitive proxy statements |
| Mar 13, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 13, 2025 | 10-K | Annual Report |
| Mar 13, 2025 | 8-K | Current Report |
| Mar 5, 2025 | PRE 14A | Other preliminary proxy statements |
| Mar 5, 2025 | 8-K | Current Report |